Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very unusual activity today, all weakness is being met with buying, something we have not seen in quite some time.
Definitely not a good sign if they have to dilute again without being able to come up with any partnership for anything since the last dilution. Maybe there is a slim chance they will announce something before the offering, but it's not looking good.
Unfortunately no. If this is already pricing in another offering, seems like it would need to be a very small offering in that case.
You think the market has this priced in already? I would have expected more damage than this, although it has gotten pretty bad this afternoon.
Part of me is hoping that the refiling has something to do with some expectation of selling an amount of shares that gets close to the shelf limit, which would require a stock price closer to 10, but that's a dream.
That's the thing, I can't tell if the market has no confidence in the technology, or no confidence in the team to execute, or both. Potential partners might have similar concerns. Hard to explain why this tech with at least some potential seems to be valued at 0.
The ulterior motives have never proven to be true in the past.
Just like last time when the additional shares were authorized, it was because a deal was coming.
I wouldn't expect any great news from the conference call, if there is great news it will be announced before that (or possibly after). The only possible "good" news would be that AXAL is shelved and there are associated cost savings, and the market reacts positively, which is possible.
Not so far, not great but it could be a lot worse.
Seems like the market is not too fazed by this, maybe it was expected.
Have they ever gone to this conference? I don't remember it. In any case, they can't afford to go.
Apparently it's very easy!
No news is probably not great news, though clearly not bad news.
I wouldn't completely rule it out, but probably takes two partnerships, one for AXAL and one for HOT. As we know, said partnerships have been very hard to come by.
Although Ken did not explicitly say the next conference call is a deadline for an AXAL partnership, I think for all practical purposes, it is. If we make it to the conference call with no partnership, most likely AXAL will wind down.
In that case, I don't quite understand the relevance of your comment about Keytruda being approved for metastatic cervical cancer.
Although it's clearly not a crime against humanity if this trial is halted, I think it's a little bit of an overstatement to say that nobody would notice simply because the goal of this trial is to prevent metastasis. For many cancers, preventing metastasis is most of the battle, and if successful the patient can often beat the disease. Of course local recurrence is also a big risk, but in many or most cases the fight is effectively lost once metastasis happens, and I would claim it's certainly preferable to prevent metastasis than treat it after it happens.
Looking like today could be near record low volume.
If this is a creeping takeover, whoever they might be, they are doing an outstanding job of not inflating the share price.
I wouldn't quite call it baseless, the lack of any partnerships for anything over the last 2 years could be a basis for concluding there will not be a deal now. I'm not saying that's my prediction, but there is some basis for such a prediction.
I really think DOC knew they needed cash and wanted to do another offering, but the BOD said no and thought TL could instead get some partnerships. That might also partially explain why they forged ahead with the MAA application, thinking it would improve the chances of finding a partner for AXAL.
Wouldn't the NEO deal at least have needed tacit BOD approval?
Not so sure about that, I think a concrete announcement that AXAL is being shelved and a reduction in the burn rate may be taken as a positive. Even more so if there is also a decent milestone payment from AMGN.
I kind of wonder if the second hold did them in, the EMA may have decided that the safety profile and amount of testing is not good enough based simply on that.
Unfortunately that pretty much sums it up.
One thing I will say is that the ownership reports are kind of like the short interest report - lagging information. This is all water under the bridge, and may explain the drop to the low 1's a month or so ago, and may also explain why there has been some support recently. Still a lot of potential for NEO and maybe HOT, but desperately need to shore up the balance sheet, one way or other.
Hoping the low volume is mostly summer doldrums, but might not be.
I agree the micro and millisecond transaction times are only benefiting the HFT guys and not really anyone else. A simple solution would be for the exchanges to implement a random delay in fulfilling transactions of from 100 to 1000 milliseconds, this would make the quick transactions much more difficult to be profitable, and largely eliminate the ability to act quickly on news, etc.. The delay might have to be longer than a maximum of 1 second, but it would be a good start. Such a delay would hardly matter to the average investor.
I don't think ADXS ever stated there was some bigger relationship with AMGN, it was more that they were refining the whole NEO approach along with AMGN, and that's why it took longer to get started.
According to Dew, the going concern issue will not come up again until the financial audit early next year. If the burn rate is low enough, and with even this little bit of extra cash, it may not be an issue. Almost certainly would not be an issue if any partnership emerges before that time.
If they did use the ATM recently, that could have been $5-7M, and if the AMGN milestone is $10M then they could have made a substantial improvement in the runway. May be enough to defer any additional dilution for at least 6+ months.
Actually, considerably less than 4 months, right now.
Not, but a good test today to see if it can recover.
You refer to the milestones like they are money in the bank, whereas the reality is that much of that milestone money is likely dependent on future sales of a product, so that money is a long ways off and far from guaranteed. The better question is why would AMGN pay $500M now when they might have to pay in the future only if the product is wildly successful? Also, in the end the one time payments are not worth very much, there has to be a product with a long run time. The only way ADXS gets to a high valuation is to have better proof of a real product down the road.
It seems you are going to have to make the sarcasm even more obvious for most of this crowd.
I think my eyes may be deceiving me, but it looks like ADXS has been up 4 days in a row. If history is any gauge, it will mean several days of misery in the near future.
Yep, everything is coming up roses.
Volume this low is not good for anybody.
Now two months since Ken stated limited time for an AXAL partnership, not looking too promising. I suppose something could still come along, but looks more and more like the next announcement will be to shelve AXAL, and it might be taken as a positive by the market.
I know I have said it a few times now, but the extremely low volume these days is really a problem. Something better change over the next few weeks.